{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:16:29Z","timestamp":1790946989948,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FE785\/4-2"],"award-info":[{"award-number":["FE785\/4-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.omtn.2023.05.016","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:28:53Z","timestamp":1684301333000},"page":"923-936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lipid nanoparticle-encapsulated, chemically modified anti-adenoviral siRNAs inhibit hepatic adenovirus infection in immunosuppressed Syrian hamsters"],"prefix":"10.1016","volume":"32","author":[{"given":"Anja","family":"Geisler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette","family":"Dieringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Elsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Klingel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klopfleisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Vornlocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kurreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-4350","authenticated-orcid":false,"given":"Henry","family":"Fechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.05.016_bib1","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/1873-3468.13576","article-title":"Adenovirus persistence, reactivation, and clinical management","volume":"593","author":"Lion","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2023.05.016_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bj.2021.08.009","article-title":"Human adenovirus infections in pediatric population - an update on clinico-pathologic correlation","volume":"45","author":"Shieh","year":"2022","journal-title":"Biomed. J."},{"key":"10.1016\/j.omtn.2023.05.016_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12519-022-00568-8","article-title":"Current status of human adenovirus infection in China","volume":"18","author":"Mao","year":"2022","journal-title":"World J. Pediatr."},{"key":"10.1016\/j.omtn.2023.05.016_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/infdis\/172.3.629","article-title":"Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology","volume":"172","author":"Khoo","year":"1995","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtn.2023.05.016_bib5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0031-1283287","article-title":"Adenovirus","volume":"32","author":"Lynch","year":"2011","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.omtn.2023.05.016_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/pbc.21120","article-title":"Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia","volume":"50","author":"Steiner","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omtn.2023.05.016_bib7","doi-asserted-by":"crossref","first-page":"ofab092","DOI":"10.1093\/ofid\/ofab092","article-title":"Human adenovirus 11 in 2 renal transplant recipients: suspected donor-derived infection","volume":"8","author":"Sherman","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.omtn.2023.05.016_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcv.2016.07.002","article-title":"Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Hubmann","year":"2016","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.omtn.2023.05.016_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"Florescu","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtn.2023.05.016_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jpids\/piy049","article-title":"Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric hematopoietic cell transplant recipients","volume":"8","author":"Fisher","year":"2019","journal-title":"J.\u00a0Pediatric Infect. Dis. Soc."},{"key":"10.1016\/j.omtn.2023.05.016_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jmv.21071","article-title":"Quantitative temporal and spatial distribution of adenovirus type 2 correlates with disease manifestations and organ failure during disseminated infection","volume":"80","author":"Forstmeyer","year":"2008","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.omtn.2023.05.016_bib12","doi-asserted-by":"crossref","first-page":"e13496","DOI":"10.1111\/tid.13496","article-title":"Detection of adenovirus hepatitis and acute liver failure in allogeneic hematopoietic stem cell transplant patients","volume":"23","author":"Onda","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.omtn.2023.05.016_bib13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jiac.2015.08.018","article-title":"Fulminant adenovirus hepatitis after hematopoietic stem cell transplant: retrospective real-time PCR analysis for adenovirus DNA in two cases","volume":"21","author":"Kawashima","year":"2015","journal-title":"J.\u00a0Infect. Chemother."},{"key":"10.1016\/j.omtn.2023.05.016_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/PAS.0000000000000834","article-title":"Adenovirus hepatitis: clinicopathologic analysis of 12 consecutive cases from a single institution","volume":"41","author":"Schaberg","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.omtn.2023.05.016_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s15010-020-01484-7","article-title":"Adenovirus diseases: a systematic review and meta-analysis of 228 case reports","volume":"49","author":"Gu","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.omtn.2023.05.016_bib16","first-page":"987","article-title":"Efficacy of brincidofovir in pediatric stem cell transplant recipients with adenovirus infections","volume":"10","author":"Ehlert","year":"2021","journal-title":"J Pediatric Infect. Dis. Soc."},{"key":"10.1016\/j.omtn.2023.05.016_bib17","first-page":"e19865","article-title":"Adenoviral infections in bone marrow transplanted adult patients: a review of the 44 cases reported in the last 25 years","volume":"13","author":"Keramari","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.omtn.2023.05.016_bib18","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/v14071459","article-title":"Fulminant adenoviral-induced hepatitis in immunosuppressed patients","volume":"14","author":"Kager","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2023.05.016_bib19","doi-asserted-by":"crossref","first-page":"e13776","DOI":"10.1111\/tid.13776","article-title":"Cidofovir, a choice for salvage treatment of cytomegalovirus infection in patients with haploidentical hematopoietic stem cell transplantation","volume":"24","author":"Yin","year":"2022","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.omtn.2023.05.016_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtn.2023.05.016_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtn.2023.05.016_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3851\/IMP3047","article-title":"Biological antivirals for treatment of adenovirus infections","volume":"21","author":"Schaar","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.omtn.2023.05.016_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.antiviral.2010.08.002","article-title":"Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions","volume":"88","author":"Eckstein","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.omtn.2023.05.016_bib24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00705-007-0951-z","article-title":"Silencing E1A mRNA by RNA interference inhibits adenovirus replication","volume":"152","author":"Chung","year":"2007","journal-title":"Arch. Virol."},{"key":"10.1016\/j.omtn.2023.05.016_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2012.03.011","article-title":"Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery","volume":"94","author":"Kneidinger","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.omtn.2023.05.016_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2012.10.008","article-title":"An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs","volume":"97","author":"Ibri\u0161imovi\u0107","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.omtn.2023.05.016_bib27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.omtn.2017.07.002","article-title":"Anti-adenoviral artificial MicroRNAs expressed from AAV9 vectors inhibit human adenovirus infection in immunosuppressed Syrian hamsters","volume":"8","author":"Schaar","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.05.016_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omtn.2023.05.016_bib29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2023.05.016_bib30","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.05.016_bib31","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.05.016_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2023.05.016_bib33","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1021\/acs.bioconjchem.0c00366","article-title":"The biomolecular corona of lipid nanoparticles for gene therapy","volume":"31","author":"Francia","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2023.05.016_bib35","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.05.016_bib36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0021-9258(19)85022-6","article-title":"Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes","volume":"264","author":"Bisgaier","year":"1989","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2023.05.016_bib37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1369\/0022155411410885","article-title":"Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery","volume":"59","author":"Shi","year":"2011","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.omtn.2023.05.016_bib38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41419-020-2571-4","article-title":"Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease","volume":"11","author":"Woitok","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2023.05.016_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1556\/EuJMI.4.2014.1.2","article-title":"Human adenovirus: viral pathogen with increasing importance","volume":"4","author":"Ghebremedhin","year":"2014","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"10.1016\/j.omtn.2023.05.016_bib40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/CMR.00052-07","article-title":"Adenoviruses in immunocompromised hosts","volume":"21","author":"Echavarr\u00eda","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.omtn.2023.05.016_bib41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbrc.2007.06.177","article-title":"Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs","volume":"361","author":"Sioud","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2023.05.016_bib42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/nat.2017.0680","article-title":"Effect of chemical modifications on aptamer stability in serum","volume":"27","author":"Kratschmer","year":"2017","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2023.05.016_bib43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2023.05.016_bib44","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1261\/rna.7254905","article-title":"Stability of 3' double nucleotide overhangs that model the 3' ends of siRNA","volume":"11","author":"O'Toole","year":"2005","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2023.05.016_bib45","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/mt.2012.276","article-title":"Application of mutated miR-206 target sites enables skeletal muscle-specific silencing of transgene expression of cardiotropic AAV9 vectors","volume":"21","author":"Geisler","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.05.016_bib46","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.05.016_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2014.10.005","article-title":"Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model","volume":"112","author":"Tollefson","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.omtn.2023.05.016_bib48","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.0800200105","article-title":"Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model","volume":"105","author":"Toth","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.05.016_bib49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity - 'one and done' or 'slower and lower'?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2023.05.016_bib50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.antiviral.2015.05.010","article-title":"Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir","volume":"120","author":"Pozzuto","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.omtn.2023.05.016_bib51","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In\u00a0vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2023.05.016_bib52","doi-asserted-by":"crossref","first-page":"e13243","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2023.05.016_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.05.016_bib54","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s42255-019-0124-x","article-title":"Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity","volume":"1","author":"Seitz","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.omtn.2023.05.016_bib55","doi-asserted-by":"crossref","first-page":"e0146710","DOI":"10.1371\/journal.pone.0146710","article-title":"Inhibition of hepatitis C virus in mice by a small interfering RNA targeting a highly conserved sequence in viral IRES pseudoknot","volume":"11","author":"Moon","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.05.016_bib56","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.05.016_bib57","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2169\/internalmedicine.45.1699","article-title":"Adenovirus fulminant hepatic failure","volume":"45","author":"Nakazawa","year":"2006","journal-title":"Int. Med."},{"key":"10.1016\/j.omtn.2023.05.016_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1399-3062.2009.00452.x","article-title":"Disseminated adenovirus infection in renal transplant recipients","volume":"12","author":"Saquib","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.omtn.2023.05.016_bib59","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1478-3231.2006.01342.x","article-title":"Role of Kupffer cells in host defense and liver disease","volume":"26","author":"Bilzer","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.omtn.2023.05.016_bib60","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omtn.2023.05.016_bib61","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.05.016_bib62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2023.05.016_bib63","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in\u00a0vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.05.016_bib64","doi-asserted-by":"crossref","first-page":"e1976","DOI":"10.1002\/rmv.1976","article-title":"A review on current status of antiviral siRNA","volume":"28","author":"Qureshi","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.omtn.2023.05.016_bib65","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/nar\/gkt852","article-title":"Miravirsen (SPC3649) can inhibit the biogenesis of miR-122","volume":"42","author":"Gebert","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.05.016_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.healun.2015.08.012","article-title":"ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients","volume":"35","author":"Gottlieb","year":"2016","journal-title":"Heart Lung Transplant"},{"key":"10.1016\/j.omtn.2023.05.016_bib67","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3851\/IMP1798","article-title":"RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study","volume":"16","author":"Gish","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.omtn.2023.05.016_bib68","doi-asserted-by":"crossref","first-page":"e1001997","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial","volume":"13","author":"Dunning","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.omtn.2023.05.016_bib69","doi-asserted-by":"crossref","first-page":"e1009705","DOI":"10.1371\/journal.ppat.1009705","article-title":"SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney","volume":"17","author":"Francis","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtn.2023.05.016_bib70","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tvjl.2010.10.018","article-title":"The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas","volume":"190","author":"Klopfleisch","year":"2011","journal-title":"Vet. J."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123001348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123001348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:15:20Z","timestamp":1730736920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123001348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":69,"alternative-id":["S2162253123001348"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.05.016","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticle-encapsulated, chemically modified anti-adenoviral siRNAs inhibit hepatic adenovirus infection in immunosuppressed Syrian hamsters","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}